Xenon Pharmaceuticals (Xenon Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals 3-Year Dividend Growth Rate?

Xenon Pharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Xenon Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

XENE's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Xenon Pharmaceuticals's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Xenon Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Xenon Pharmaceuticals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Xenon Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

Xenon Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Xenon Pharmaceuticals (NAS:XENE) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Xenon Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.621
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

XP0:Germany

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Executives

Gary Patou	director
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover	director	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone	director	200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer	director, officer: PRESIDENT & CEO	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney	officer: Chief Medical Officer	200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio	officer: Chief Legal Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin	officer: Chief Financial Officer	200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin	officer: SVP Bus. & Corp. Development	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield	officer: SVP, Drug Discovery	200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von	officer: Chief Commercial Officer	200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W